Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IONS
  • CUSIP: 46433010
  • Web:
  • Market Cap: $6.6867 billion
  • Outstanding Shares: 123,965,000
Average Prices:
  • 50 Day Moving Avg: $51.61
  • 200 Day Moving Avg: $46.37
  • 52 Week Range: $24.58 - $57.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -453.50
  • P/E Growth: -4.87
Sales & Book Value:
  • Annual Revenue: $420.05 million
  • Price / Sales: 16.06
  • Book Value: $1.63 per share
  • Price / Book: 33.39
  • EBIDTA: $33.51 million
  • Net Margins: -4.80%
  • Return on Equity: -14.61%
  • Return on Assets: -2.21%
  • Debt-to-Equity Ratio: 2.59%
  • Current Ratio: 5.64%
  • Quick Ratio: 5.60%
  • Average Volume: 1.39 million shs.
  • Beta: 3.15
  • Short Ratio: 7.67

Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, May, 9th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. The firm had revenue of $110.30 million for the quarter, compared to analyst estimates of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The business's quarterly revenue was up 199.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.52) earnings per share. View Ionis Pharmaceuticals' Earnings History.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

14 brokerages have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

What are analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/12/2017)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
  • 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
  • B. Lynne Parshall Esq., Chief Operating Officer, Corporate Secretary, Director
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
  • Richard S. Geary Ph.D., Senior Vice President - Development
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
  • Sarah Boyce, Chief Business Officer
  • Spencer R. Berthelsen M.D., Independent Director
  • Breaux B. Castleman, Independent Director

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Creative Planning (0.02%), Sit Investment Associates Inc. (0.02%), Aperio Group LLC (0.01%), US Bancorp DE (0.00%), Bank of Montreal Can (0.00%) and Capstone Asset Management Co. (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Sit Investment Associates Inc., Creative Planning and Capstone Asset Management Co.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Aperio Group LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $54.42.

MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  652
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $44.00 (19.15% downside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/12/2017BMO Capital MarketsReiterated RatingOutperform$59.00 -> $62.00LowView Rating Details
7/10/2017Stifel NicolausReiterated RatingHold$42.00MediumView Rating Details
5/22/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$64.00LowView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
3/10/2017Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$28.00 -> $25.00HighView Rating Details
1/6/2017Jefferies Group LLCReiterated RatingSell$17.00N/AView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
12/27/2016LaidlawBoost Price TargetBuy$59.00 -> $65.00N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00N/AView Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
2017 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)$0.16$0.05
Q2 20172($0.38)$0.19($0.10)
Q3 20172($0.31)$0.22($0.05)
Q4 20172($0.30)$0.23($0.04)
(Data provided by Zacks Investment Research)


Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 88.72%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.00View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.15View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.00View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.00View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.50View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.00View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.00View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.00View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.00View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.00View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.00View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.50View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.00View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline logoPro-Trader Daily: Featured Company News - Ionis Receives $10 Million Payment from Biogen - July 19 at 10:20 PM logoFeatured Company News - Ionis Receives $10 Million Payment from Biogen - July 19 at 10:20 PM logoAkcea Therapeutics Announces Closing of Initial Public Offering - July 19 at 10:20 PM logoIonis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB) - July 18 at 9:50 PM logoIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Sells $865,425.00 in Stock - July 18 at 7:25 PM logoIonis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB) - - July 18 at 2:27 AM logoIonis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration - July 18 at 2:27 AM logoAkcea Therapeutics Announces Pricing of Initial Public Offering - July 14 at 4:23 AM logoIonis Pharmaceuticals' (NASDAQ:IONS) "Outperform" Rating Reaffirmed at BMO Capital Markets - July 12 at 11:50 AM logoNew Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen - July 11 at 5:59 AM logoNew Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome (FCS) - July 11 at 5:59 AM logoIonis: Bullish Boost From Phase 3 Data - Seeking Alpha - July 10 at 7:55 PM logoStifel Nicolaus Reiterates Hold Rating for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - July 10 at 6:36 PM logoTheStreet Upgrades Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to "C-" - July 7 at 2:42 PM logoCommit To Purchase Ionis Pharmaceuticals At $43, Earn 14.7% Annualized Using Options - - July 7 at 6:31 AM logoIonis Pharamaceuticals: Will Bullish Charts and Quant Upgrade Lead to Breakout? - July 7 at 6:31 AM logoBiogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA) - July 4 at 4:45 PM logoStanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock - July 3 at 7:29 PM logoBrett P. Monia Sells 309 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock - July 3 at 7:28 PM logoAkcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO - Seeking Alpha - June 28 at 4:11 AM logoIonis Pharmaceuticals, Inc. (IONS) Given Consensus Recommendation of "Hold" by Analysts - June 27 at 12:14 PM logo$83.59 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter - June 25 at 10:04 AM logoZacks: Brokerages Anticipate Ionis Pharmaceuticals, Inc. (IONS) to Post -$0.20 EPS - June 23 at 8:33 AM logoIonis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease - - June 22 at 6:07 PM logoETFs with exposure to Ionis Pharmaceuticals, Inc. : June 22, 2017 - June 22 at 6:07 PM logoIonis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease - June 22 at 1:05 PM logoEnrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017 - June 22 at 1:05 PM logoAkcea Therapeutics Launches Proposed Initial Public Offering - June 20 at 6:51 PM logoUnderstanding Ionis Phamaceuticals’ Revenue Stream in 1Q17 - June 14 at 7:54 PM logoAkcea Therapeutics’ Volanesorsen: 1Q17 Performance - June 13 at 10:54 AM logoDevelopments for Ionis Pharmaceuticals after 1Q17 - June 13 at 10:54 AM logoETFs with exposure to Ionis Pharmaceuticals, Inc. : June 12, 2017 - June 12 at 6:32 PM logoChanges in Ionis Pharmaceuticals’ Valuation after 1Q17 - June 9 at 8:30 PM logoIonis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 - June 9 at 9:36 AM logoWhy Ionis Pharmaceuticals Inc. Swooned 6% in May - Motley Fool - June 7 at 11:30 PM logoIonis Pharmaceuticals Inc (IONS) Short Interest Update - June 6 at 3:46 PM logoWhy Ionis Pharmaceuticals Inc. Swooned 6% in May - June 6 at 10:25 AM logoIonis Pharma (IONS) Confirms SPINRAZA Approval in European Union; Earns $50M Milestone Payment - June 2 at 7:24 PM logoIonis Pharmaceuticals' (IONS) Buy Rating Reiterated at BMO Capital Markets - June 2 at 1:14 PM logoIonis Pharmaceuticals Inc (IONS) Receives Average Recommendation of "Hold" from Analysts - June 2 at 9:00 AM logoSPINRAZA® (nusinersen) Approved in the European Union - PR Newswire (press release) - June 1 at 8:22 PM logoIonis Pharma (IONS) Confirms SPINRAZA Approval in European ... - - June 1 at 3:22 PM logoIonis Pharmaceuticals Reaches Analyst Target Price - Nasdaq - June 1 at 3:22 PM logoSPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy - June 1 at 3:22 PM logoSPINRAZA® (nusinersen) Approved in the European Union - June 1 at 3:22 PM logoBiogen, Ionis Stocks Pop After Europe Approves $125,000 Drug - June 1 at 3:22 PM logoZacks: Analysts Anticipate Ionis Pharmaceuticals Inc (IONS) Will Post Quarterly Sales of $83.59 Million - June 1 at 1:14 PM logoIonis Pharmaceuticals Inc (IONS) Expected to Post Earnings of -$0.24 Per Share - May 30 at 9:10 AM logoAkcea Announces Publication in The New England Journal of ... - PR Newswire (press release) - May 27 at 6:17 PM logoIonis Pharma (IONS) Announces Publication in NEJM of Data with AKCEA-ANGPTL3-L Rx Showing Favorable ... - - May 27 at 4:43 AM



Ionis Pharmaceuticals (IONS) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff